SKYE SKYE BIOSCIENCE INC revenue, earnings and financials
For the quarter ended June 30, 2026, SKYE BIOSCIENCE INC reported revenue of n/a, net income of −$10.8M and diluted EPS of −$0.27; for the fiscal year ended December 2025 revenue was n/a.
SKYE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$58.2M, net income −$55.9M (margin n/a), EPS −$1.41
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$30.2M, net income −$26.6M (margin n/a), EPS −$0.73
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$34.7M, net income −$37.6M (margin n/a), EPS −$5.37
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$18.3M, net income −$19.5M (margin n/a), EPS −$8.77
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$7.85M, net income −$8.52M (margin n/a), EPS −$0.02
SKYE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$10.8M, EPS −$0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$12.5M, EPS −$0.32
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$14.4M, EPS −$0.37
- Quarter ended Sep 30, 2025: revenue n/a, net income −$12.8M, EPS −$0.32
- Quarter ended Jun 30, 2025: revenue n/a, net income −$17.6M, EPS −$0.44
- Quarter ended Mar 31, 2025: revenue n/a, net income −$11.1M, EPS −$0.28
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$9.75M, EPS −$0.25
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.90M, EPS −$0.10
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.90M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.02M, EPS −$0.18
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.42M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$24.9M, EPS −$3.17
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.11M, EPS −$0.80
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.17M, EPS −$1.37
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.89M, EPS −$7.17
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.13M, EPS −$1.58
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.42M, EPS −$0.01
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.04M, EPS −$0.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.51M, EPS $0.00
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.82M, EPS $0.00
SKYE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$43.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$25.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$14.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$12.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$6.47M, share buybacks n/a
SKYE balance sheet
- Jun 30, 2026: cash $8.07M, total assets $11.0M, total liabilities $11.5M, shareholders' equity −$497K
- Mar 31, 2026: cash $8.15M, total assets $19.4M, total liabilities $10.4M, shareholders' equity $9.01M
- Dec 31, 2025: cash $5.88M, total assets $28.3M, total liabilities $8.29M, shareholders' equity $20.0M
- Sep 30, 2025: cash $18.4M, total assets $41.3M, total liabilities $8.49M, shareholders' equity $32.8M
- Jun 30, 2025: cash $23.8M, total assets $52.2M, total liabilities $8.48M, shareholders' equity $43.7M
- Mar 31, 2025: cash $46.4M, total assets $64.8M, total liabilities $5.54M, shareholders' equity $59.3M
- Dec 31, 2024: cash $68.4M, total assets $72.8M, total liabilities $4.61M, shareholders' equity $68.2M
- Sep 30, 2024: cash $67.4M, total assets $81.5M, total liabilities $5.73M, shareholders' equity $75.8M
Is SKYE profitable?
No. SKYE BIOSCIENCE INC lost $50.5M over the last four quarters.
What is SKYE's EPS?
Diluted earnings per share over the last four quarters were −$1.28; −$0.27 in the latest quarter.